Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 KRANKHEITSBILD NETZWERK REGISTRY PROJEKTE ANMELDEN
 
 
  
Wet Biomarkers -
--->Aktuelles
[-]Das Projekt
--->Sponsor
--->[+]Vorstand
--->[+]Writing Committee Strategic ...
--->[-]Wissenschaftl. Begutachtung
--->Becanovic
--->Busse
--->Frontali
--->Giorgini
--->Holmans
--->Mariotti
--->Norremolle
--->Reetz
--->Rickards
--->Saft
--->van Duijn
--->Valenza
--->Verellen
--->Öffentliche Dokumente
--->Zentrale Koordination
--->Länderkoordination
--->Fellowship Programme
--->[-]Constitution
--->Article 1
--->Article 2
--->Article 3
--->Article 4
--->Article 5
--->Article 6
--->Article 7
--->Article 8
--->Article 9
--->Article 10
--->Article 11
--->Article 12
--->Documents
--->[-]Voting/Nomination
--->[-]Mitglieder
--->Antrag
[-]Standorte
--->[+]Österreich
--->[+]Belgien
--->[+]Tschechische Republik
--->[+]Dänemark
--->[+]Finnland
--->[+]Frankreich
--->[+]Deutschland
--->[+]Ireland
--->[+]Italien
--->[+]Niederlande
--->[+]Norwegen
--->[+]Polen
--->[+]Portugal
--->[+]Russia
--->[+]Spanien
--->[+]Schweden
--->[+]Schweiz
--->[+]U.K.
--->[+]Outside Europe
[-]Arbeitsgruppen
--->[+]Advanced HD
--->[+]Psychiatrischer Phänotyp
--->[+]Biologische Modifizierer
--->[+]Biomarker
--->[+]Hirngewebedatenbank
--->[-]Kognitiver Phänotyp
--->[+]Termine
--->[+]Treffen
--->[+]Environmental Modifiers
--->[+]Funktionelle Fähigkeit
--->[+]Genetische Tests/Beratung
--->[+]Modifizierende Gene
--->[+]Gesundheitsökonomie
--->[+]Bildgebende Verfahren
--->[+]Juvenile HK
--->[+]Motorischer Phänotyp
--->[+]Neuroprotektive Therapie
--->[+]Physiotherapie
--->[+]Lebensqualität
--->[-]Behandlungstandards
--->[+]Termine
--->[+]Meetings
--->[+]Dieticians
--->[+]SALT
--->[+]Dental care
--->[+]Occupational
--->[+]Chirurgische Ansätze
--->[+]Symptomatische Therapie
--->[+]Young Adults
[-]Veranstaltungen
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[+]EHDN 2006
--->[+]EHDN 2005
--->[+]EHDN 2004
[-]Kommunikation
--->Kontakt
--->Chat
--->Mailinglisten - Öffentlich
--->Newsletter
--->Stellenangebote
DatumBeschreibungGrößeAutor Dokument 
03.08.26Selisistat: potential pharmacodynamic readouts based on transcriptomics32 kBanonymousapplication/mswordf04-potential-pharmacodynamic-readouts 
03.08.26Mutant Huntingtin fragmentation in immune cells tracks Huntington’s Disease progression32 kBanonymousapplication/mswordf05-mutant-huntingtin-fragmentation 
03.08.26Whole blood SAGE digital gene expression profiling from Huntington's disease patients32 kBanonymousapplication/mswordf03-blood-sage-digital-gene-expression 
03.08.26Selisistat: Soluble htt protein levels as a potential pharmacodynamic readout32 kBanonymousapplication/mswordf02-soluble-htt-protein-levels 
03.08.26Establishment of novel assays for quantification of full-length wild-type and mutant Huntingtin by using the AlphaLISA technology32 kBanonymousapplication/mswordf01-establishment-novel-assays 
03.08.26A critical evaluation of inflammatory markers in Huntington’s Disease plasma32 kBanonymousapplication/mswordf06-critical-evaluation-inflammatory-m... 
03.08.26Cross-sectional and longitudinal associations between CRP and neuropsychiatric symptoms in HD32 kBanonymousapplication/mswordf07-crp-neuropsychiatric-symptoms 
03.08.26Abnormal regulation of macrophage-derived transforming growth factor – β 1 (TGF-β1) production in Huntington Disease32 kBanonymousapplication/mswordf12-abnormal-regulation-of-macrophage 
03.08.268OHdG is not a biomarker for Huntington’s Disease; lessons for future biomarker studies32 kBanonymousapplication/mswordf14-8ohdg 
03.08.26Progredient deterioration of hepatic mitochondrial function in Huntington's Disease – measured by using the 13C-methionin breath test32 kBanonymousapplication/mswordf11-progredient-deterioration-hepatic-... 
03.08.26The study on molecular changes related to energy metabolism in Huntington’s disease subjects - looking for biomarkers32 kBanonymousapplication/mswordf09-molecular-changes-related-to-energ... 
03.08.26The autoimmune profile of Huntington`s Disease patients - a pilot study32 kBanonymousapplication/mswordf08-autoimmune-profile 
03.08.26A new biomarker in Huntington's disease32 kBanonymousapplication/mswordf15-new-biomarker 

Verzeichnis enthält 13 Dokumente.
impressum | datenschutz | haftungsausschluss | nutzungsbedingungen